Trending Topic

Musculoskeletal AI image
16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked
Samantha Cooray, Alexander Deng, Tim Dong

There is much excitement about the deployment of artificial intelligence (AI) in healthcare, and the musculoskeletal field is no exception. In this article, we introduce some of the latest developments relating to osteoarthritis (OA), osteoporosis, rheumatoid arthritis (RA) (as an example of inflammatory arthritis), connective tissue disease (CTD), Ehlers–Danlos syndrome (EDS) and musculoskeletal surgical interventions. […]

Xavier Mariette, EULAR 2021: Belimumab plus Rituximab in Primary Sjögren’s Syndrome

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jul 2nd 2021

It was a delight to catch up with Professor Xavier Mariette (Université Paris-Saclay and Hôpital Bicêtre, Paris, France) around the phase 2 study investigating subcutaneous belimumab and intravenous rituximab in primary Sjögren’s syndrome.

The abstract ‘SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY.’ (OP0135) was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.

Questions

  1. What is the rationale for B-cell depletion using belimumab plus rituximab in people with primary Sjögren’s syndrome? (0:15)
  2. Could you tell us a little about the Phase 2 study, its clinical endpoints, and how well the endpoints were met? (1:09)
  3. What will be the next steps in the clinical development of this combination in primary Sjögren’s syndrome? (2:25)

Disclosures: Xavier Mariette discloses honorarium from BMS, GSK, Novartis, Pfizer, Servier, UCB and a research grant from Ose Pharmaceutics.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of EULAR 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup